Drug intelligence / Profile preview

AKF-1

Development stage: Unknown
Lead developer: Akorn Holdings
Modality: Small Molecules
Administration: Ophthalmic

Overview

AKF-1 is a small molecule drug initially developed by Akorn. It has been investigated primarily for the treatment of eye diseases, specifically acute allergic conjunctivitis. The drug was evaluated in a Phase 3 clinical trial as an ophthalmic solution to assess its onset and duration of action in treating acute allergic conjunctivitis using the conjunctival allergen challenge model. Its mechanism of action and molecular target have not been explicitly disclosed in public sources. The highest reported development status is "Pending," with no evidence of regulatory approval or commercial launch[1].

Beyond the preview

Go deeper on AKF-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKF-1.

Explore the full profile